Vinikoor, Michael J.Sinkala, EdfordKanunga, AnnieMuchimba, MutintaNsokolo, BrightChilengi, RomaWandeler, GillesMulenga, JosephChisenga, TinaBhattacharya, DebikaSaag, Michael S.Foster, GrahamFried, Michael W.Kelly, Paul2025-09-172018-Sep-210.4254/wjh.v10.i9.622https://pubs.cidrz.org/handle/123456789/12111AIM: To characterize antiviral therapy eligibility among hepatitis B virus (HBV)-infected adults at a university hospital in Zambia. METHODS: Hepatitis B surface antigen-positive adults ( RESULTS: The median age was 33 years, 71.9% were men, and 30.9% were diagnosed with HBV through a clinically-driven test with the remainder identified CONCLUSION: Approximately one in ten HBV-monoinfected Zambians were eligible for antivirals. Many had indeterminate phenotype and needed clinical follow-up.https://pubmed.ncbi.nlm.nih.gov/30310540/